scholarly journals Creutzfeldt-Jakob disease: results of an inquiry in the fifteen Member States of the European Union

1996 ◽  
Vol 1 (6) ◽  
pp. 42-45 ◽  
Author(s):  
B. C. Merkel ◽  
P. W.J Peters ◽  
L Chambaud

Creutzfeldt-Jakob Disease (CJD) was first described in 1920-1921. CJD is a rare disease with a reported incidence of 0.5 to 1 case per million people in Europe. This fatal dementia belongs to the category of Transmissible Spongiform Encephalopathies (TSE)

2021 ◽  
Author(s):  
Joseph Bruno Bidin Brooks ◽  
Fábio César Prosdócimi ◽  
Fernanda Stoffel Covolan ◽  
Iane Rocha Holanda ◽  
Amanda Medeiros de Lucena ◽  
...  

Context: Creutzfeldt-Jakob disease (CJD) is a rare disease that belongs to the category of transmissible spongiform encephalopathies. The condition is invariably fatal and progresses with severe dementia with psychiatric signs and, with cortical, subcortical and cerebellar signs. This case report was approved by the Ethics Committee of Universidade Metropolitana de Santos. Case Report: We present the case of a 59-year-old male patient who presented with a subacute onset of behavioral changes associated with myoclonus and changes in coordination. Associated with the described symptoms, he presented aphasia of expression, cerebellar incoordination and spasticity was also present in the four limbs. Conclusions: The usual forms of transmission could not be confirmed for this patient, who died four months after the onset of symptoms.


2007 ◽  
Vol 88 (12) ◽  
pp. 3486-3492 ◽  
Author(s):  
Darren M. Green ◽  
Victor J. del Rio Vilas ◽  
Colin P. D. Birch ◽  
Jethro Johnson ◽  
Istvan Z. Kiss ◽  
...  

Following the bovine spongiform encephalopathy (BSE) crisis, the European Union has introduced policies for eradicating transmissible spongiform encephalopathies (TSEs), including scrapie, from large ruminants. However, recent European Union surveillance has identified a novel prion disease, ‘atypical’ scrapie, substantially different from classical scrapie. It is unknown whether atypical scrapie is naturally transmissible or zoonotic, like BSE. Furthermore, cases have occurred in scrapie-resistant genotypes that are targets for selection in legislated selective breeding programmes. Here, the first epidemiological study of British cases of atypical scrapie is described, focusing on the demographics and trading patterns of farms and using databases of recorded livestock movements. Triplet comparisons found that farms with atypical scrapie stock more sheep than those of the general, non-affected population. They also move larger numbers of animals than control farms, but similar numbers to farms reporting classical scrapie. Whilst there is weak evidence of association through sheep trading of farms reporting classical scrapie, atypical scrapie shows no such evidence, being well-distributed across regions of Great Britain and through the sheep-trading network. Thus, although cases are few in number so far, our study suggests that, should natural transmission of atypical scrapie be occurring at all, it is doing so slowly.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 5151-5151
Author(s):  
Louise Watson ◽  
Peter Wyld ◽  
Daniel Catovsky

Abstract Introduction: While Chronic Lymphocytic Leukemia (CLL) is considered a rare disease, to our knowledge the current prevalence of the condition within the European Union (EU) member states is not published. Understanding the number of individuals with CLL is vital to assess disease burden within the wider population. Methods: Using 2002 data from the International Agency for Research on Cancer (IARC), we estimated the number of individuals with CLL (ICD-10 C91.1) from those reported for all leukemias (C91–95) and extrapolated the figures by the population increase within the EU between 2002 and 2006, the last year with fully updated Community population estimates. One-year and 5-year partial prevalence estimates are reported (i.e. the number of individuals still living 1 and 5 years post diagnosis). We then applied proportional estimates from the literature to assess those requiring immediate treatment, those under observation and their likely progression rates. Results: We found that within the 27 EU states plus Iceland, Norway and Lichtenstein, 1-year and 5-year CLL partial prevalence estimates totalled approximately 13,952 and 46,633 individuals respectively in 2006. If we apply Rai or Binet staging to the 1-year estimate, up to 45% of patients will be Stage III/IV or B/C and require immediate treatment. Thus 6,278 individuals may be treated within the first year of diagnosis. Of 55% (7673) under observation, by five years up to 33% (2,532) may have more advanced disease with increased risk of mortality. Conclusion: While CLL is a rare disease, the number of individuals burdened by the disease within the EU is considerable and thousands of patients require treatment and physician care, which has cost implications for member states.


Sign in / Sign up

Export Citation Format

Share Document